Development of Autoantibodies in the TrialNet Natural History Study

摘要

OBJECTIVEUnderstanding the relationship between age and islet autoantibody (Ab) seroconversion can establish the optimal screening interval(s) to assess risk for type 1 diabetes, identify subjects who can participate in prevention trials, and determine associated costs. This study assessed the rates of seroconversion to glutamic acid decarboxylase positive (GAD65⁺), insulin positive (mIAA⁺), and insulinoma-associated protein 2 positive (ICA512⁺) in a large cohort of relatives of type 1 diabetes probands undergoing Ab rescreening in the TrialNet Natural History Study.